Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Helix Biopharm (HBP.TO)

Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 40,152
  • Shares Outstanding, K 229,441
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,290 K
  • 60-Month Beta -0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 64.55
Trade HBP.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date 04/24/24 [--]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +4,995,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1600 +9.38%
on 04/02/24
0.2100 -16.67%
on 03/22/24
-0.0150 (-7.89%)
since 03/15/24
3-Month
0.1600 +9.38%
on 04/02/24
0.2500 -30.00%
on 03/04/24
-0.0400 (-18.60%)
since 01/16/24
52-Week
0.1500 +16.67%
on 10/19/23
0.2600 -32.69%
on 10/11/23
-0.0450 (-20.45%)
since 04/17/23

Most Recent Stories

More News
Helix Biopharma: Fiscal Q1 Earnings Snapshot

Helix Biopharma: Fiscal Q1 Earnings Snapshot

HBP.TO : 0.1750 (-12.50%)
Helix Biopharma: Fiscal Q4 Earnings Snapshot

Helix Biopharma: Fiscal Q4 Earnings Snapshot

HBP.TO : 0.1750 (-12.50%)
Stocks in play: Helix BioPharma Corp.

Will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 ...

HBP.TO : 0.1750 (-12.50%)
Helix Biopharma: Fiscal Q3 Earnings Snapshot

Helix Biopharma: Fiscal Q3 Earnings Snapshot

HBP.TO : 0.1750 (-12.50%)
Helix Biopharma: Fiscal Q2 Earnings Snapshot

Helix Biopharma: Fiscal Q2 Earnings Snapshot

HBP.TO : 0.1750 (-12.50%)
Helix Biopharma: Fiscal Q1 Earnings Snapshot

Helix Biopharma: Fiscal Q1 Earnings Snapshot

HBP.TO : 0.1750 (-12.50%)
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Company")...

HBP.TO : 0.1750 (-12.50%)
Helix Biopharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology,...

HBP.TO : 0.1750 (-12.50%)
Stocks in play: Helix BioPharma Corp

Is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021. ...

HBP.TO : 0.1750 (-12.50%)
Stocks in play: Helix BioPharma Corp.

Provided a corporate update on initiatives that were undertaken by the Company in 2021. Despite the ...

HBP.TO : 0.1750 (-12.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1833
2nd Resistance Point 0.1817
1st Resistance Point 0.1783
Last Price 0.1750
1st Support Level 0.1733
2nd Support Level 0.1717
3rd Support Level 0.1683

See More

52-Week High 0.2600
Fibonacci 61.8% 0.2180
Fibonacci 50% 0.2050
Fibonacci 38.2% 0.1920
Last Price 0.1750
52-Week Low 0.1500

See More

Business Summary

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar